{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:23:42Z","timestamp":1759940622571},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1993,1,1]],"date-time":"1993-01-01T00:00:00Z","timestamp":725846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1993]]},"DOI":"10.1007\/bf00685030","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T07:25:51Z","timestamp":1101713151000},"page":"423-430","source":"Crossref","is-referenced-by-count":16,"title":["Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies"],"prefix":"10.1007","volume":"31","author":[{"given":"K. S.","family":"Sridhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. S. A.","family":"Samy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sauerteig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. L.","family":"Wellham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Y.","family":"Anac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ardalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. W.","family":"Benedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM197902083000603","volume":"300","author":"J Alexander","year":"1979","unstructured":"Alexander J, Dainiak N, Berger HJ, et al. (1979) Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278","journal-title":"N Engl J Med"},{"key":"CR2","first-page":"1416","volume":"37","author":"RS Benjamin","year":"1977","unstructured":"Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37: 1416","journal-title":"Cancer Res"},{"key":"CR3","first-page":"795","volume":"69","author":"AB Benson III","year":"1985","unstructured":"Benson AB III, Trump DL, Koeller JM et al. (1985) Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 69: 795","journal-title":"Cancer Treat Rep"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/mpo.2950130408","volume":"13","author":"F Bessho","year":"1985","unstructured":"Bessho F, Kinumaki H, Kobayashi M, et al. (1985) Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med Pediatr Oncol 13: 199","journal-title":"Med Pediatr Oncol"},{"key":"CR5","first-page":"247","volume":"6","author":"RH Blum","year":"1975","unstructured":"Blum RH (1975) An overview of studies with Adriamycin (NSC-123127) in the United States. Cancer Chemother Rep 6: 247","journal-title":"Cancer Chemother Rep"},{"key":"CR6","first-page":"42","volume":"4","author":"B Cantwell","year":"1985","unstructured":"Cantwell B, Buamah P, Harris AL (1985) Phase I and II study of oral verapamil (VRP) and intravenous vindesine (VDN) (abstract). Proc Am Soc Clin Oncol 4: 42","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.1985.3.8.1127","volume":"3","author":"BI Carr","year":"1985","unstructured":"Carr BI, Bertrand M, Browning S, et al. (1985) A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study. J Clin Oncol 3: 1127","journal-title":"J Clin Oncol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/1097-0142(19871101)60:9<2165::AID-CNCR2820600908>3.0.CO;2-C","volume":"60","author":"BI Carr","year":"1987","unstructured":"Carr BI, Blayney DW, Goldberg DA, et al. (1987) High doses of prochlorperazine for cisplatin-induced emesis: a prospective, random, dose-response study. Cancer 60: 2165","journal-title":"Cancer"},{"key":"CR9","first-page":"83","volume":"9","author":"BI Carr","year":"1990","unstructured":"Carr BI, Morgan R, Doroshow JH, et al. (1990) Phase I clinical study of 24 hour continuous infusion prochlorperazine (Compazine) (abstract). Proc Am Soc Clin Oncol 9: 83","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.1989.7.4.415","volume":"7","author":"WS Dalton","year":"1989","unstructured":"Dalton WS, Grogan TM, Meltzer PS, et al. (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415","journal-title":"J Clin Oncol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/1097-0142(19900501)65:9<1895::AID-CNCR2820650904>3.0.CO;2-R","volume":"65","author":"A Figueredo","year":"1990","unstructured":"Figueredo A, Arnold A, Goodyear M, et al. (1990) Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer: a phase I\/II study. Cancer 65: 1895","journal-title":"Cancer"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF00435836","volume":"23","author":"WN Hait","year":"1989","unstructured":"Hait WN, Morris S, Lazo JS, et al. (1989) Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine. Cancer Chemother Pharmacol 23: 358","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00685716","volume":"27","author":"J-M Jacquet","year":"1990","unstructured":"Jacquet J-M, Bressolle F, Galtier M, et al. (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27: 219","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/bjc.1990.244","volume":"62","author":"RD Jones","year":"1990","unstructured":"Jones RD, Kerr DJ, Harnett AN, et al. (1990) A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62: 133","journal-title":"Br J Cancer"},{"key":"CR15","volume-title":"Resistance to antineoplastic drugs","author":"D Kessel","year":"1989","unstructured":"Kessel D (1989) Resistance to antineoplastic drugs, 1st edn. CRC, Boca Raton, Florida","edition":"1st edn."},{"key":"CR16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1083\/jcb.66.1.188","volume":"66","author":"A Krishan","year":"1975","unstructured":"Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188","journal-title":"J Cell Biol"},{"key":"CR17","first-page":"3895","volume":"40","author":"A Krishan","year":"1980","unstructured":"Krishan A, Ganapathi R (1980) Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res 40: 3895","journal-title":"Cancer Res"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cyto.990080311","volume":"8","author":"A Krishan","year":"1987","unstructured":"Krishan A, Sridhar KS, Davila E, et al. (1987) Patterns of anthracycline retention modulation in tumor cells. Cytometry 8: 306","journal-title":"Cytometry"},{"key":"CR19","first-page":"253","volume":"6","author":"IH Krakoff","year":"1975","unstructured":"Krakoff IH (1975) Adriamycin (NSC-123 127) studies in adult patients. Cancer Chemother Rep 6: 253","journal-title":"Cancer Chemother Rep"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1200\/JCO.1988.6.5.880","volume":"6","author":"RL Miller","year":"1988","unstructured":"Miller RL, Bukowski RM, Budd GT, et al. (1988) Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I\/II trial. J Clin Oncol 6: 880","journal-title":"J Clin Oncol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0277-5379(89)90104-1","volume":"25","author":"IN Olver","year":"1989","unstructured":"Olver IN, Webster LK, Bishop JF, et al. (1989) A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy. Eur J Cancer Clin Oncol 25: 1457","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.1987.5.4.641","volume":"5","author":"RF Ozols","year":"1987","unstructured":"Ozols RF, Cunnion RE, Klecker RW et al. (1987) Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 641","journal-title":"J Clin Oncol"},{"key":"CR23","first-page":"83","volume":"9","author":"PA Philip","year":"1990","unstructured":"Philip PA, Monkman S, Idle J, et al. (1990) A phase I study of nifedipine with etoposide in metastatic tumours (abstract). Proc Am Soc Clin Oncol 9: 83","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000421-198608000-00016","volume":"9","author":"CA Presant","year":"1986","unstructured":"Presant CA, Kennedy PS, Wiseman C, et al. (1986) Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 9: 355","journal-title":"Am J Clin Oncol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00685031","volume":"31","author":"C Ramachandran","year":"1993","unstructured":"Ramachandran C, Sauerteig A, Sridhar KS, Krishan A (1993) MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemother Pharmacol 31: 431","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR26","first-page":"108","volume":"3","author":"H Roche","year":"1984","unstructured":"Roche H, Hyman G, Nahas G, et al. (1984) Unexpected efficacy of prochlorperazine (P) IV in preventing cisplatin-induced emesis (abstract). Proc Am Soc Clin Oncol 3: 108","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR27","first-page":"74","volume":"9","author":"B Samuels","year":"1990","unstructured":"Samuels B, Ratain M, Safa A, et al. (1990) Phase I trial of vinblastine (VBL) with continuous infusion (CI) cyclosporine-A (CSA) as a modulator of multidrug resistance (MDR) (abstract). Proc Am Soc Clin Oncol 9: 74","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR28","first-page":"1403","volume":"70","author":"N Savaraj","year":"1986","unstructured":"Savaraj N, Lu K, Dimery I, et al. (1986) Clinical pharmacology of homoharringtonine. Cancer Treat Rep 70: 1403","journal-title":"Cancer Treat Rep"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/1097-0142(19901115)66:10<2082::AID-CNCR2820661007>3.0.CO;2-5","volume":"66","author":"KS Sridhar","year":"1990","unstructured":"Sridhar KS, Samy TSA, Agarwal RP, et al. (1990) A phase I study of 4?-0-tetrahydropyranyladriamycin. Cancer 66: 2082","journal-title":"Cancer"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00007691-198901000-00002","volume":"11","author":"TW Sweatman","year":"1989","unstructured":"Sweatman TW, Lokich JJ, Israel M (1989) Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit 11: 3","journal-title":"Ther Drug Monit"},{"key":"CR31","first-page":"74","volume":"9","author":"J Verweij","year":"1990","unstructured":"Verweij J, Herweijer H, Planting ASTH, et al. (1990). In vitro and in vivo studies on the effect of cyclosporin-A (Cy-A) in the circumvention of clinical multidrug resistance (MDR) (abstract). Proc Am Soc Clin Oncol 9: 74","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00685030\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:10:10Z","timestamp":1554459010000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00685030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1993]]}},"alternative-id":["BF00685030"],"URL":"https:\/\/doi.org\/10.1007\/bf00685030","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993]]}}}